THYROID DYSFUNCTION IN BREAST CANCER (literature review)
Keywords:
thyroid dysfunction, breast cancer, hypothyroidAbstract
Analysis of modern literature indicates the relevance of the problem being studied and indicates that antitumor drugs, widely used in the treatment of patients with malignant neoplasms, can have undesirable side effects on the thyroid gland and other endocrine organs, which, in turn, can affect the results of treatment and quality of life of patients. Clinicians should be familiar with the adverse effects of medications on the endocrine organs, as well as their management. Complex patients with hormonal disorders may have the right to a multidisciplinary approach to solving the problem with the involvement of an experienced endocrinologist. There are no known strategies to prevent thyroid disease in patients receiving new anticancer agents. Algorithms for the prevention and treatment of dysfunction of the thyroid gland, as well as other endocrine organs, in cancer patients receiving antitumor drug therapy require their own development.
References
Abrosimov A.Y., Ilin A.Y. Clinical and morphological characteristics of follicular tumors of the thyroid gland in young people living in areas contaminated with radionuclides. //Problemi endocrinologii. — 2000. № 6. — p. 7-12. (in Russ)
Beknazarov Z.P. Reconstructive plastic surgery in combined and complex treatment of stage III breast cancer / dissertation of PhD, - 2011., - 21 p. (in Russ)
Ibragimova G.V. News of applied immunology and allergology. М., 2000. - p. 4-18. (in Russ)
Ognerubov N.A., Kushlinskiy A.V., Tkacheva I.A. Endocrine system in diseases of the mammary glands. SnP., 1998. - p. 15-23, 4550. (in Russ)
Rimareva Е.А. The effect of chemotherapy treatment for breast cancer on the structure and function of the thyroid gland / dissertation of PhD., - 2005., - 16 р. (in Russ)
Tillyashaykhov М.N. ey al. The state of oncology services in the Republic of Uzbekistan in 2022 / Тashkent, -2023., - 184 р. (in Russ)
Тотоyan E.S. Reproductive function of women with thyroid pathology. // Journal Acusherstvo and gynecology. 1994. - №1. - p. 8-11. (in Russ)
Hartmann K. Thyroid Disorders in the Oncology Patient // J. Adv. Pract. Oncol. — 2015 (Mar-Apr.). — Vol. 6, №2. — P. 99-106.
Bianchi L., Rossi L., Tomao F. et al. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma // Endocr. Relat. Cancer. — 2013 (Aug.). — Vol. 19; 20, №5. — P. 233-245.
Riksfjord Hamnvik O.P., Reed Larsen P., Marqusee E. Thyroid Dysfunction from Antineoplastic Agent // J. Natl. Cancer Inst. — 2011. Nov 2. —Vol. 103, №21. — P. 1572-1587.
Carter Y., Sippel R., Chen H. Hypothyroidism After a Cancer Diagnosis: Etiology, Diagnosis, Complications, and Management // Oncologist. — 2014 Jan. — Vol. 19, №1. — P. 34-43.
McDougall I.R.Thyroid diseases after treatment of Hodgkin’s disease // N. Engl. J. Med. — 1991 Aug. — Vol. 29, № 325 (9). — P. 599-605.
Surks M.I., Sievert R. Drugs and Thyroid Function Review Article // N. Engl. J. Med. — 1995. — Vol. 333. — P. 1688-1694.
Betty J. Dong. How medications affect thyroid function // West J. Med. — 2000 Feb. — Vol. 172, №2. — P. 102-106.
Giani C., Fierabracci P., Bonacci R. Relationship between breast cancer and thyroid disease: relevance of autoimmune thyroid disorders in breast maliqnancy. //J Clin Endocrinol Metabol. 1996. - Vol. 81/ - 3:990994/
Gittoes N.J. Drug-induced thyroid disorders // Drug. Saf. — 1995 Jul. — Vol. 13, №1. — P. 46-55.
Harjai K.J., Licata A.A., Alton O. Effects of amiodarone on thyroid function // Ann. Intern Med. — 1997 Jan. 1. — Vol. 126, №1. — P. 63-73.
Okumura Y., Takeda Y., Sato S. Comparison of diffential diagnostic capabilities of 201 TI scintigraphy and fine-needle aspiration of thyroid nodules. //J.Nucl. Med. 2000. - Vol. 12. - P. 7-12.
Koh L.K, Greenspan F.S., Yeo P.P. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature // Thyroid. — 1997 Dec. — Vol. 7, №6. — P. 891-896.
Kleiner J., Altshuler L., Hendrick V., Hershman J.M. Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment // J. Clin. Psychiatry. — 1999 Apr. — Vol. 60, №4. — P. 249-55.
Davies P.H., Franklyn J.A. The effects of drugs on tests of thyroid function // Eur. J. Clin. Pharmacol. — 1991. — Vol. 40, №5. — P. 439-51.
Jonasch E., Haluska F.G. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities // Oncologist. — 2001. — Vol. 6, №1. — P. 34-55.
Tomer Y., Blackard J.T., Akeno N. Interferon alpha treatment and thyroid dysfunction // Endocrinol. Metab. Clin. North. Am. — 2007 Dec. — Vol. 36, №4. — P. 1051-66.
24. Shakhanova Shakhnoza , Rakhimov Nodir , Zaripova Parvina . Breast tumors in adolescent girls // Journal of Biomedicine and Practice. 2022, vol . 7, issue3, pp.266-273
Quach A., Ji L., Mishra V. et al. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131I-MIBG) therapy for neuroblastoma // Pediatr. Blood Cancer. — 2011 Feb. — Vol. 56, №2. — P. 191-201.
Faris J.E., Moore A.F., Daniels G.H. Sunitinib (sutent)- induced thyrotoxicosis due to destructive thyroiditis: a case report // Thyroid. — 2007 Nov. — Vol. 17, №11. — P. 1147-9.
Torino F., Corsello S.M., Longo R. et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy // Nat. Rev. Clin. Oncol. — 2009 Apr. — Vol. 6, №4. — P. 219-28.
Bryan R. Haugen Drugs that suppress TSH or cause central hypothyroidism // Best Pract. Res. Clin. Endocrinol. Metab. — 2009 Dec. — Vol. 23, №6. — P. 793-800.
Lodish M.B., Stratakis C.A. Endocrine side effects of broad-acting kinase inhibitors // Endocr. Relat. Cancer. — 2010 Aug. — Vol. 16; 17, №3. — P. 233-44.
Polatova Djamila , Madaminov Ahmad, Raximov Nodir . Significance of expression PD-L1 and p53 proteins in human papillomavirus-associated oropharyngeal squamous cell carcinoma Journal of Biomedicine and Practice. 2022, vol . 7, issue 4, pp . 144-151
Статья поступила в редакцию 12.03.2024; одобрена после рецензирования 24.04.2024; принята к публикации 25.04.24.
The article was submitted 12.03.2024; approved after reviewing 24.04.2024; accepted for publication 25.04.2024.
Информация об авторах:
Азимова Махбуба Аброрбек кизи – базовый докторант Ташкентского педиатрического медицинского института, Ташкент, Узбекистан. Е-mail: azimovamakhbuba@gmail.com
Насырова Хуршидахон Кудратиллаевна - д.м.н., доцент, заведующая кафедрой эндокринологии Ташкентского педиатрического медицинского института, Ташкент, Узбекистан. ORCID: https://orcid.org/0000-0002-8104-5037
Источники финансирования: Работа не имела специального финансирования.
Конфликт интересов: Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.
Вклад авторов:
Азимова М.А. — сбор материала, непосредственное проведение исследования, написание текста;
Насырова Х.К. — идеологическая концепция работы, редактирование.
Tashkent pediatric medical institute, Uzbekistan.
Information about the authors:
Azimova A. Makhbuba — researcher Tashkent pediatric medical institute, Uzbekistan. Е-mail: azimovamakhbuba@gmail.com
Nasirova K. Khurshidakhon — DSc, deputy director, head of department of Tashkent pediatric medical institute, Uzbekistan. ORCID: https://orcid.org/0000-0002-8104-5037
Sources of funding: The work did not receive any specific funding.
Conflict of interest: The authors declare no explicit or potential conflicts of interest associated with the publication of this article.
Contribution of the authors:
Azimova A. Makhbuba —writing the text; editing the article;
Nasirova K. Khurshida — ideological concept of the work, editing the article;
